Archive | Redefining Early Stage Investments RSS feed for this section

NIH at Digital RESI September

27 Aug

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

The Small Business Education and Entrepreneurial Development (SEED) Group at the National Institutes of Health (NIH) is leading a panel at RESI September on the product development pipeline. SEED is advancing the cause of scientific innovation in healthcare through collaborating with the buyers and sellers in life science to enhance relationships, products, and technology. Fundraising CEOs, strategic partners, and investors can take advantage of the opportunity to learn from the SEED team. Read below to learn more about the panel and click here to register for Digital RESI September.

NIH is SEEDing the Product Development Pipeline 

Small Business Education and Entrepreneurial Development (SEED) Group, Changing the Game for Life Science Innovators

SEED supports the NIH innovator community in their efforts to validate the potential health impacts of promising scientific discoveries and advance them into healthcare products that improve patient care and enhance health. Developing products across the biomedical spectrum requires NIH’s collaboration with universities and research institutions, small businesses, trade associations and societies, angel investors, venture capitalists, and strategic partners. SEED leads initiatives that develop these relationships and build opportunities for NIH innovators to further their product development efforts.

Matthew McMahon, PhD, Director, SEED, NIH

Matt leads the SEED Office to accelerate NIH-funded biomedical innovations from bench to bedside. SEED supports a comprehensive translational research ecosystem that includes a national network of academic proof-of-concept centers and a small business program that invests over $1 billion annually in a portfolio of more than 1500 life science companies. SEED also provides technical and entrepreneurial advisory services and builds relationships with business, finance, and healthcare stakeholders to ensure these innovations will impact patients’ lives. Matt has a diverse background in academia, biomedical small business, congressional policy, and NIH program development and management. His previous experience also includes service as the principal scientist for the bionic eye company Second Sight Medical Products and as a staff member on both the United States Senate and House of Representatives committees responsible for science, technology, and innovation policy.

Stephanie Fertig, MBA, HHS Small Business Program Lead, NIH

Ms. Stephanie J. Fertig is the HHS Small Business Program Lead in SEED (Small business Education and Entrepreneurial Development) at the National Institutes of Health (NIH). She currently oversees the Health and Human Services (HHS) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which includes the NIH SBIR and STTR programs. The HHS SBIR and STTR programs are congressionally mandated set-aside programs that provide over $1.2 billion dollars per year to small business concerns. Prior to joining SEED, she managed the SBIR and STTR Programs at the National Institute of Neurological Disorders and Stroke (NINDS). During her over 15 years at NIH she has led the development and implementation of multiple programs focused on small businesses and translational research. Ms. Fertig has a Bachelor of Science degree in Chemistry with a major in Physics from the University of Virginia and a Master of Business Administration from the University of Maryland’s Robert H. Smith School of Business.

Chris Sasiela, PhD, Team Lead, Innovator Support, SEED

Dr. Sasiela has over a decade of experience providing support and consultation to academic innovators and small businesses engaged in therapeutic, device, and diagnostic development programs. As the Innovator Support Team Lead in SEED (Small business Education and Entrepreneurial Development) in the Office of Extramural Research at the National Institutes of Health, Chris coordinates the activities of a team of seasoned professionals with experience in product and business strategy, business development, fundraising, partnerships, reimbursement, and regulatory affairs. Chris is passionate about enabling NIH’s innovator community to progress their discoveries as far as science and human biology permit. Starting her career as a researcher, Chris worked in basic research at the University of Southern California and the University of Maryland, and in drug discovery, development, and improvement groups at Baxter, the Department of the Army, and the National Cancer Institute. Chris transitioned from a research to a regulatory career path via an Interagency Oncology Taskforce Fellowship at the US Food and Drug Administration. Continuing her regulatory career path at Social & Scientific Systems, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute, Chris deepened her experience working with product development researchers understand, develop, and execute regulatory plans to get their innovative technologies from ideas to first-in-human and beyond. She regularly conducts project-focused consultations, delivers educational seminars, and develops regulatory resources for internal and external audiences. Dr. Sasiela earned a bachelor’s degree in chemistry from Whittier College, a Ph.D. in Pharmaceutical Sciences from the University of Maryland, School of Pharmacy, and has maintained Regulatory Affairs Certification status from the Regulatory Affairs Professional Society since 2011.

John Sullivan, MBA, Entrepreneur-in-Residence, SEED

John Sullivan has been a leader in healthcare technology innovation throughout his career, with extensive experience in operating, investing in, developing and acquiring market-leading businesses. Prior to the NIH, John worked with healthcare leaders such as Cardinal Health (VP, Strategy and Business Development) and Boston Scientific. He was a Partner with Foundation Medical Partners, a national healthcare venture capital firm with financial backing from the Cleveland Clinic. He also helped to start Molecular Staging Inc., a biotechnology tools company spun out of Yale University School of Medicine. Working with Yale University founders, he helped grow the company to over 100 employees, develop its product and service lines, and ultimately sell the company to Qiagen, a global life sciences company. He has served on the boards of directors of Semprus Biosciences (acquired, Teleflex), Coapt Systems (acquired, MicroAire), KEW Group, and Direct Flow Medical and held board observer roles at BridgePoint Medical (acquired, Boston Scientific) and Explorys (acquired, IBM). John earned a BS in Industrial Engineering degree with distinction from Stanford University and an MBA from the Stanford University Graduate School of Business.

RESI September Panel Spotlight: Digital Health Investors

20 Aug

By Karen Deyo, Senior Investor Research Analyst, LSN

There has been a large paradigm shift in healthcare delivery this calendar year and adapting to this digital age will require adoption of new technologies, providing a great opportunity for up-and-coming digital health companies to showcase themselves. At our upcoming Digital RESI conference taking place September 14-16, the panelists will discuss how investing in digital health has changed, which technologies are gaining the most traction, and how to approach investors in the current industry landscape.

We are happy to introduce the speakers participating on the Digital Health Investors panel!

Moderator: Robert Garber, Partner at 7wire Ventures

For over 25 years, Robert Garber has worked with early-stage healthcare and technology companies, co-managing three venture funds with $200M+AUM and holding leadership positions with three high-growth companies. Robert is currently a Partner at 7wire Ventures, where he focuses on investments in digital healthcare and technology-enabled services that empower consumers to be better stewards of their health and healthcare expenditures. 7wireVentures is an early stage, healthcare venture firm that supports entrepreneurs who focus on empowering the Connected Informed Health Consumer to create great companies and change the status quo. 7wire believes that mobile, connected platforms, the cloud, and sophisticated insights will improve the efficiency of the healthcare system and improve outcomes for all.

Evan Cohen, Associate Principal, Strategic Investing at Healthbox

Evan is part of the investment team for the DaVita Venture Fund. Previously, he led M&A and strategic payer activities at Genoa Healthcare (OptumRx division), the country’s leading behavioral health pharmacy, telepsychiatry and medication management services company. Evan joined Genoa Healthcare through the acquisition of 1DocWay, where
he managed clinic-based telepsychiatry sales. He was formerly a healthcare investment banker at Piper Jaffray, where he advised biopharmaceutical, medical device, and healthcare services companies on capital raising and M&A transactions. Evan began his career at BlackRock, where he served as a fixed income product specialist managing institutional client business totaling nearly $100B AUM. Evan resides in New York City and received his BA in Economics from Northwestern University and his MBA from Columbia Business School.

Roy Wiesner, Managing Director at aMoon Fund

Roy Wiesner is a Managing Director at aMoon Fund, Israel’s largest life sciences and healthtech VC. He focuses on early-stage investments, primarily in digital health and medical devices. Prior to joining aMoon, he was the CEO of a Cleantech incubator and seed-stage fund owned by CK Hutchison (Fortune 500 company), where he was also involved in forming a number of ventures. Roy was previously a corporate lawyer, specializing in M&A, Private Equity and VC transactions, working for international law firm Weil Gotshal in New York and Hong Kong, and as a partner for a prominent law firm in Tel Aviv. He holds an LL.B from the Hebrew University and a dual MPA from the LSE and Columbia University.

Ben Evans, Investment Director at InHealth Ventures

Ben started his career as a doctor in the NHS before working in the UK and US across early stage medtech, management consultancy and hospital management. He has a particular interest in technologies that can improve the working lives of clinical and non-clinical healthcare staff.


Netalie Nadivi, Partner at TriVentures

Netalie has 20 years of professional experience in technology start-up and global corporate environments. Netalie’s interdisciplinary and holistic background, working with start-ups from different vantage points throughout her career, contributes greatly to the evaluation and identification of investment opportunities and portfolio management.

Netalie spent over a decade at Philips in various corporate capacities including Director of Business Development and M&A. She brings with her tremendous transaction and project management experience in investments, strategic partnerships, acquisitions and post-merger integration spanning across several industries including healthcare and consumer health and wellness.

Prior to her time at Philips, Netalie gained experience in a technology start-up and an accelerator that set up companies from stage zero. In both positions, Netalie held senior multidisciplinary CEO support roles where she was responsible for the companies’ business, legal and financial affairs.

Netalie holds a M.S. in Management from Boston University and a B.A. in Legal Studies from the University of California at Berkeley.

This panel will be live-streamed on Wednesday, September 16, 2020 at 2:00 pm EDT – Make sure to register for RESI to join this and other exciting panels!

Check Out Our Digital RESI September Panel Line Up!

13 Aug

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN


With one month left until the next Digital Redefining Early Stage Investments (RESI) September Conference (September 14-16), we are very excited to highlight some of the key speakers who will be contributing to our virtual panels.

These speakers are all investors and strategic partners who actively invest in and work with early-stage life science and healthcare companies, with diverse interests within therapeutics, medical devices, diagnostics, and digital health.

Digital RESI September registrants get to hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and more.

Here are some of the panelists joining us:

Jun Deng
Investment Partner
Joyance Partners

Prathna Ramesh
Executive Director
Maple Leaf Angels (MLA)

Nancy Torres Kaufman
Beacon Capital

Steve Yoder
Vice President, Business Development
Taiho Oncology Inc

Duncan Young
Director, Search and Evaluation Oncology, BD&L

Barbara Lavery
Chief Program Officer
Alliance for Cancer Gene Therapy

Mark Krul
Aglaia Oncology Funds

Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation
Daiichi Sankyo

Fiona Mack
Head of JLABS TMCx
Johnson & Johnson Innovation

Chris Haskell
VP, Head of West Coast Innovation Center

Yao Li Ho
Senior Director of Business Development
LYFE Capital

Haolin Sung
Managing Partner
Chaperone Investment

Christina Salys
Sr. Mgr. New Business Development
Intuitive Surgical

Rupert Winckler
Head of EMEA New Business Development
Olympus Corporation

William Dai
Founding Partner
ShangBay Capital

Benedikt Luhmann
Principal – Healthcare
VI Partners

Norm Gitis
Founder, Managing Partner
Lymo Ventures

Paul Larkin
Manager, Research Innovation
Crohn’s and Colitis Foundation

Michael Cole
Founder and General Partner
Global Neurohealth Ventures

Lore Gruenbaum
Vice President, Therapy Acceleration Program
Leukemia & Lymphoma Society (LLS)

Kuldip Dave
Vice President of Research
ALS Association

Chris Penland
VP BioPharma Programs
Cystic Fibrosis Foundation

Mayank Taneja
Director of Venture Investments
OSF Healthcare Ventures

Cyril Philip
Providence Ventures

Rajesh Aggarwal
Executive Vice President
Jefferson Strategic Ventures

Linda Maxwell
Biomedical Zone

Ron Paliwoda
Founder and President
Paliwoda Group

Marcia Dawood
Managing Partner
Individual Angel

Merom Klein
Entrepreneur Mentor
Keiretsu Forum

Laura Davis
Managing Director
Golden Seeds

Rob Manning
Cherrystone Angel Group

Sascha Berger
TVM Capital Life Science

Haruhiko Sugino
Director, Global Business Development
Otsuka Pharmaceuticals

Bibhash Mukhopadhyay
New Enterprise Associates

Jayson Punwani
Senior Partner
Takeda Ventures

Scott Weiner
Amzak Health

Roy Wiesner
Managing Director
aMoon Fund

Robert Garber
7wire Ventures

Evan Cohen
Associate Principal, Strategic Investing

Ben Evans
Investment Director
InHealth Ventures

Netalie Nadivi

Rick Jones

Katherine Hill Ritchie
Nottingham Spirk Family Office

Mark Ralph
Executive Director
Boehringer Ingelheim Venture Fund

Please contact if you are interested in any speaking opportunities!

A Week of Partnering: An Interview with Life Science Nation (LSN) Chief Conference Officer, Greg Mannix

6 Aug

Greg Mannix

By Rory McCann, Marketing Manager & Conference Producer, LSN

Rory McCann

When it comes to the fundraising CEO on the lookout for strategic partners, it’s essential to be both visible and active in the partnering scene. Partnering is a relationship that requires frequent attention over time. One well-timed conversation rarely cuts a deal in healthcare, but it’s the CEOs who show up regularly and prepared that catch the eye of their ideal partners.

This is why Life Science Nation (LSN) is pairing their successful RESI conference series with their new partnering event, 4D Meets AI. Artificial intelligence (AI) has countless applications in healthcare, and this conference is highlighting the most advanced and powerful applications across drugs, devices, diagnostics, and digital health (4Ds). The team that has connected hundreds of fundraising CEOs to investors in relationships resulting in millions of invested capital now brings AI to center-stage as a companion to the wildly successful RESI conference series. In this interview, LSN Chief Conference Officer, Greg Mannix pulls back the curtain on why the team has built a week of partnering, and what 4D Meets AI is bringing to these essential conversations.

Rory McCann (RM): Let’s start with RESI. What is the difference between the Digital RESI 2-day partnering event and Digital RESI September?

Greg Mannix (GM): First of all, Digital RESI September has 3 full days of partnering, so the potential for getting a lot of meetings is really amazing. I have seen some attendees get upwards of 40 meetings over the 3 days of our June conference. Another difference is that this is a full RESI conference, meaning that there will be new and insightful investor and workshop panels, the Innovation Challenge, the Featured Company Pitch Sessions and a virtual Exhibit Hall. All of this great content is aimed at adding value for fundraising CEOs.

RM: RESI is very popular with early-stage companies. How can a company stand out and get increased visibility at RESI?

GM: One of the ways companies can get more traction with investors and strategic partners is through the Innovation Challenge. It is free to apply and participate, and the selected finalists are tagged as such in their partnering profiles for investors to see, and they get their own dedicated landing page on the conference live agenda. CEOs can submit an Innovation Challenge Application until August 12.

Another great option is to pitch to a panel of investors. The Featured Company Pitch Sessions put a company’s 4-minute pitch in front of a panel of 5 focused investors. There is a live Q&A session, and afterwards the pitching companies can follow up with the investor panelists. Participating companies also get their own dedicated landing page. It’s really a unique opportunity available to CEOs for a small fee for the benefit of pitching in front of lead investors that are a fit for their company and product. CEOs can submit a Pitch Sessions Applications on a rolling deadline.

RM: What’s new about RESI September?

GM: This upcoming Digital RESI will have more live-streaming content than ever before. We have found that real-time panels and pitch sessions, with the possibility of live Q&A, are very popular. We are expecting more investors than ever to participate in this global event—more than 450 expected—and companies can choose to have 1 day or 3 days of partnering. Additionally, the 4D Meets AI conference is the other huge novelty in September. This conference is a great addition to RESI, enabling attendees to access up to 5 days of partnering.

RM: Sounds like there’s a lot going on at RESI. Tell me about the new 4D Meets AI conference.

GM: 4D Meets AI is LSN’s newest conference focused on how AI is accelerating development in the 4 Ds: Drugs, Devices, Diagnostics and Digital Health. It is an incredibly dynamic field that is growing tremendously. I believe we are in a golden age of technology in the life sciences, and therefore RESI and 4D Meets AI are a showcase of some amazing people and products that will change the world and help many.

The conference will have a full track of panels focusing on the hottest new applications of AI in life science, and another track of panels with investors interested in AI-enabled technologies. To sign up for 4D Meets AI, register HERE.

RM: Lastly, fundraising CEOs are often strapped for cash. Is there a special discount to attend both conferences?

GM: Yes! Companies can save on each conference with the super early bird registration rate until August 7. If they choose to bundle for a 5-day partnering experience, they can save $200 with the combo registration which is $1,200.

Sign up for RESI, 4D Meets AI, or register for the combo deal for 5 days of continuous partnering. You won’t regret it!

Putting the AI in Taiwan: A Peek inside the Use of Intelligent Technology in Taiwan’s Life Science Ecosystem

30 Jul

Cheng-Yu Chen

An interview with Cheng-Yu Chen, VP of Taipei Medical University
By Jessica Yang, Investor Research Analyst, LSN

Jessica Yang

In recent years, Taiwan has rapidly been catching up to the global Artificial Intelligence (AI) wave, as the government, leading industries, and academic institutions have proactively worked together to make Taiwan an AI talent hub in Asia. The well-known information and communications technology (ICT) and semiconductor industry in Taiwan have established a great foundation for intelligent technology development.

I had the opportunity to speak with Cheng-Yu Chen, VP of Taipei Medical University (TMU). Dr. Chen is also the Director of the Research Center for Artificial Intelligence in Medicine at TMU. Taipei Medical University has worked with Life Science Nation (LSN) and brought its spin-off companies to attend the Redefining Early Stage Investments (RESI) conferences for multiple years. TMU is also one of the most active academic institutions in Taiwan and has built its own AI in Medicine ecosystem. This includes the Technology Commercialization Center (TMU-TCC), the Smart Hospital Simulation Lab (SHSL), an incubator/accelerator, and hospitals, which not only support AI professionals, but also help with early-stage AI companies’ fundraising and business development.

Dr. Chen shared a comprehensive perspective of Taiwan’s AI in life science developments, and how Taipei Medical University has become an AI innovation hub in Taiwan.

Jessica Yang (JY): How do you see AI in life science developments and opportunities in Taiwan?

Cheng-Yu Chen (CC): Taiwan has been seeking to develop world-leading AI infrastructure and to become an important player in the global AI value chain. Especially within the life sciences area, I think Taiwan can leverage the following advantages that make it an essential hub to develop and promote AI technology:

(1) An industry leadership position in the manufacturing of ICT & semiconductor hardware

(2) The Taiwan government’s strong support and commitment to improving the AI R&D environment

(3) A no.1 ranking in the Global Open Data Index and a high level of transparency of data-sharing

When all these data combine with our ICT industries, it provides a friendly environment for testing the application of AI. In addition, the Taiwan government’s ongoing AI action plan, which includes the intent to introduce new laws and regulations to promote AI development, also helps professionals gain access to over 20 years of data from the National Health Insurance Administration while maintaining patients’ privacy. Overall, I see lots of promising opportunities in Taiwan to incorporate AI in life sciences.

JY: What are Taipei Medical University’s current efforts and accomplishments in AI in life science development?

CC: Here at Taipei Medical University (TMU), we understand that “No data, no AI,” thus TMU established the first Graduate Institute of Biomedical Informatics in Taiwan in 1998, which cultivated a sufficient talent pool to catch up the current global AI trend. Then we followed the government’s AI action plan to build more professional programs in AI in Medicine in recent years. These programs are aimed to increase the number of medical doctors, medical technologists, and clinic professionals with a working knowledge and skills in AI.

Furthermore, we also have the Research Center for AI in Medicine, the Smart Hospital Simulation Lab (SHSL), the Technology Commercialization Center (TMU-TCC), incubators, and hospitals, all designed to advance AI technologies. A professor who has a great idea can start a company through the commercialization center, the incubator programs can help find resources, and our research centers and labs can provide systems to complete proof-of-concept. As an example, we have already curated three AI-related companies in the past two years:

(1) DermAI: AI solutions to detect Malignant Melanoma (MM) and the risk of acnes

(2) AESOP Technology: AI-based prescription error prevention solution to maximize patient safety

(3) Redica Health: Ted-ICU AI solution to help with smart hospital construction

We plan to start two more companies next year.

JY: Both DermAI and AESOP have attended RESI before! Speaking of this, does TMU have any international collaborations in AI in life science development?

CC: Yes. There are many aspects on which we work with international corporations and institutes. For example, we partnered with AstraZeneca on incubator programs and clinical trial collaboration. We have also cooperated with the Massachusetts Institute of Technology (MIT) to organize Hackathons on Health IoT programs. We also worked with Stanford University, University of Pennsylvania, and the University of California, and sent our talents to learn AI imaging and surgical planning, etc. at these institutions. For the spin-off companies I just mentioned, AESOP Technology partnered with Harvard Innovation Labs and Brigham and Women’s Hospital to complete prescription screening tests. We expect to have more collaborations worldwide in the next few years.

JY: As we know, Taiwan did a great job in in preventing COVID-19 spread – do you think AI helps with this successful response?

CC: Yes. Our government, hospitals, and research institutes all took rapid actions that made Taiwan able to develop a nationwide mask sitemap using AI in real-time, as well as an AI-applied alert system incorporated in hospitals to decrease the risk of COVID-19 spread and local transmission.

In addition, the Ministry of Science and Technology (MOST) is gathering principal investigators’ ideas to further develop preventive strategies for such a pandemic, and many are AI-related. I think that as long as Taiwan keeps an innovative mindset and grasps the advantages of AI development, we will be able to build a successful and leading ecosystem in AI in the life science arena.

As AI is playing a significant role in the healthcare arena worldwide, LSN plans to launch the inaugural 4D Meets AI partnering conference September 17 – 18, 2020. This new 4D Meets AI conference is set to provide a new platform for all companies developing Drugs, Devices, Diagnostics, and Digital Health (the 4 Ds), with an Artificial Intelligence (AI) vertical, to meet and connect with investors and strategic partners. Visit to learn more and register.

The Innovation Challenge for Digital RESI September is Accepting Applications!

30 Jul

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN


One of the biggest challenges facing fundraising CEOs working to bridge the gap between potential and partnership is the ability to stand out among a sea of promising tech and connect with the right investors for their work. Life Science Nation (LSN) wants to make the choices clearer for investors, which is why we’ve developed the Innovation Challenge for early-stage companies.  The Innovation Challenge is designed to highlight the best of the best so deserving companies can showcase their work to strategic partners.

The Innovation Challenge for the 3-Day Digital Redefining Early Stage Investments (RESI) Conference in September is now accepting applications for two weeks only, due August 12!

For fundraising life science companies, participating in the Innovation Challenge is a great way to increase visibility. All participating companies will have a dedicated landing page featuring materials (example screenshot below) that the companies can use to promote and direct traffic, just like they would do at an in-person RESI.

In addition, they will be featured on the Next Phase blog and newsletter, as well as LSN’s social networking platforms. Finalists also are indicated with a special badge within our partnering system indicating their Innovation Challenge Finalist status.

Attendees are also encouraged to vote for their favorite, most innovative companies and the Top 3 Winners who receive the most votes can receive free tickets for up to 3 future RESI Conferences of their choice.

The Innovation Challenge review team has compiled a list of guidelines to help companies with their application process:

What makes a high-score company?

The evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A perfectly scored company would have a transformational technology that can achievably address a high unmet need using a differentiable novel approach or target. Alongside high innovation, differentiation, unmet need, and market fit, a high-scoring company would have a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners. The company will also receive high marks for having what we call “investor-ready” marketing material (executive summary, pitch deck, website).

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure you understand and answer the questions fully. The team has seen unclear responses as to what a company’s technology is and its significance in improvement.

Be honest with your answers.

The team frequently reviews applications that state they have no competitors in the space, when most likely, they do. Novel products do have competitors before them, for established technology does exist in the indication your product targets. Be honest with whom your competitors are, and then address what the key differentiators are to your product. Even if your product is an incremental improvement, be honest and highlight this and it can still be attractive!

For example, competitors for your disease-modifying therapeutic may be symptom-treating therapeutics in the same indication that are either commercialized or being developed. You should identify these symptom-treating therapeutics and highlight your novel target approach that makes your product disease-modifying.

Explain your current standings in detail.

Outline everything you have in terms of your current standing, while also providing your outlook of where you hope to go. Avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Provide short-range and long-term horizons.

If you do not have certain criteria, such as a strategic alliance or IP, that’s perfectly fine. State your current standing and provide what steps you are currently taking to reach that milestone. For Alliances and Collaborations, state your verbal relationships; for IP status, state how many you have filed or are planning to file. Providing your strategy is better than a simple yes or no.

Put in a balanced effort.

You should not spend 5 minutes on this application, and neither should you spend 5 hours. Your answers should be brief, as well as detailed – the team has received hasty, effortless applications that are quickly discarded with a low score. On the other hand, you also shouldn’t spend an excessive amount of time on the application, as these are all straight-forward questions that you should be comfortable answering. Remember, as your executive summary should answer all these questions alone, this application is the backbone of the evaluation process and essentially your executive summary.

Send us your marketing material.

If you have marketing material, send it. This includes your slide deck, executive summary, website, videos – any supplemental material that can boost understanding of your technology and whether your company is investor-ready. The application provides limited space – while this forces you to get straight to the point, supplemental material explains what an application cannot (i.e. figures, graphs, pipeline, non-confidential data, etc.)

Companies can submit their applications for the Digital RESI September Innovation Challenge by August 12 at here. Learn more about Digital RESI September at

Before Buying a Ticket to a Digital Partnering Event — Know You Have a Shot

23 Jul

By Rory McCann, Marketing Manager & Conference Producer, LSN

Before buying a ticket to a digital partnering event, make sure your goals are realistic and achievable, and those will differ depending on where you are at in the funding universe. (Click here for a free copy of Life Science Nation (LSN)’s Fundraising Manifesto.) The good news is that LSN is hearing from investors that, after a brief slow-down in the early months of 2020, they are closing deals and allocating funds. The big question many are asking is, “Really? Even without face-to-face meetings?” Investors give a resounding, YES!

LSN is tracking 400+ early-stage companies in drugs, devices, diagnostics, and digital health in a diverse range of indications who have raised between $150K – $33M in various funding stages as a direct result of connections made through the Redefining Early Stage Investments (RESI) partnering conferences. While old-school partnering says in-person yearly meetings are the ticket, RESI disagrees, and the numbers don’t lie.

Partnering is an ongoing conversation from pitch to capital allocation, which can often take between 9-18 months. These deals are made through first establishing the fit and then creating an ongoing dialogue that turns into a relationship. This means that it is essential to communicate and meet often via whichever platform is available, which in 2020, is online. Before committing to buying a ticket to a partnering event, it’s important to understand your chances of success, as well as what success looks like for your company, and which investors are truly qualified.

LSN gives early-stage companies a helping hand by having one-on-one interviews regularly with its global investor network to ensure every investor is vetted, as well as runs conferences and an accelerator program, manages databases, and offers a trove of free resources (Next Phase Newsletter, Bootcamps, etc.). LSN has everything an early-stage company needs to get in the game and play to win. Next week’s Digital RESI July dedicated partnering event is one of those resources we hope fundraising CEOs will take advantage of and will join our growing list of innovative companies funded through RESI. Find out more and register for next week’s 2-day dedicated partnering event at

%d bloggers like this: